The moomoo app is an online trading platform offered by Moomoo Technologies Inc. SVB Leerink analyst Andrew Berens initiates coverage on CTI BioPharma (NASDAQ:CTIC) with a Outperform rating and announces Price Target of $13.ĬTI BioPharma Eliminates Chief Operating Officer Position SVB Leerink Initiates Coverage On CTI BioPharma With Outperform Rating, Announces Price Target of $13 Within the last quarter, CTI BioPharma (NASDAQ:CTIC) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 2 0 0 0 Last 30D 0 1 0ĬTI BioPharma Initiated at Outperform by SVB Leerinkĭate Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 177.78% SVB Leerink → $13 Initiates Coverage On → Outperform 177.78% Jefferies → $13 At the end of the last trading period, Citi Trends closed at $19.44. The stock has a 52-week-high of $97.14 and a 52-week-low of $15.48. For the second quarter, Citi Trends had an EPS of $0.31, compared to year-ago quarter EPS of $1.36. Losers: NGM Biopharmaceuticals (NGM) -73%. Minerva Neurīenzinga's Top Ratings Upgrades, Downgrades For October 17, 2022įor Citi Trends Inc (NASDAQ:CTRN), Gordon Haskett upgraded the previous rating of Reduce to Hold. Gainers: Ambrx Biopharma (AMAM) +18%. MorphoSys (MOR) +10%. Personalis (PSNL) +10%. Anavex Life Sciences (AVXL) +9%. CTI BioPharma (CTIC) +9%. CTIC is a commercial-stage biopharmaceutical company launching Vonjo - a differentiĬTI BioPharma Shares Are Trading Higher After SVB Leerink Initiated Coverage on the Stock With an Outperform Rating and a $13 Price Target.ĬTI BioPharma shares are trading higher after SVB Leerink initiated coverage on the stock with an Outperform rating and a $13 price target.Īmbrx, MorphoSys Top Healthcare Gainers NGM, Minerva Lead Losers' Pack SVB Leerink initiated coverage on CTI Biopharma Corp (NASDAQ:CTIC) with an Outperform rating and a $13 price target. CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Īnalyst Thinks This Company's Bone Marrow Cancer Treatment Can 'Transform Paradigm'
0 Comments
Leave a Reply. |